Lumos Pharma Inc (NAS:LUMO)

$ 4.38 0.08 (1.86%) Market Cap: 37.88 Mil Enterprise Value: 23.84 Mil PE Ratio: 0 PB Ratio: 7.68 GF Score: 48/100

Q2 2024 Lumos Pharma Inc Earnings Call Transcript
Aug 01, 2024

$1.79 (-3.76%)

Earnings
Q1 2024 Lumos Pharma Inc Earnings Call Transcript
May 15, 2024

$2.24 (-12.16%)

Earnings
Q4 2023 Lumos Pharma Inc Earnings Call Transcript
Mar 07, 2024

$3.03 (+0.66%)

Earnings
Lumos Pharma Inc to Host Virtual KOL Event Transcript
Dec 06, 2023
Lumos Pharma Inc Phase 2 Topline Data and Q3 Report Transcript
Nov 08, 2023
Q2 2023 Lumos Pharma Inc Earnings Call Transcript
Aug 09, 2023

$3 (-5.85%)

Earnings
Lumos Pharma Inc Virtual KOL Webinar Transcript
Jun 21, 2023
Lumos Pharma Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q1 2023 Lumos Pharma Inc Earnings Call Transcript
May 03, 2023

$3.3 (+3.12%)

Earnings
Q4 2022 Lumos Pharma Inc Earnings Call Transcript
Mar 01, 2023

$3.46 (+0.58%)

Earnings
Lumos Pharma Inc To Host KOL Webinar Transcript
Dec 06, 2022
Q3 2022 Lumos Pharma Inc Interim Analysis & Earnings Call Transcript
Nov 14, 2022

$5.82 (-34.68%)

Earnings
Q2 2022 Lumos Pharma Inc Earnings Call Transcript
Aug 09, 2022

$8.1 (-5.26%)

Earnings
Q1 2022 Lumos Pharma Inc Earnings Call Transcript
May 10, 2022

$8.05

Earnings
Q4 2021 Lumos Pharma Inc Earnings Call Transcript
Mar 10, 2022

$9.52 (+0.85%)

Earnings
Q3 2021 Lumos Pharma Inc Earnings Call Transcript
Nov 03, 2021

$10.04 (+2.66%)

Earnings
Q2 2021 Lumos Pharma Inc Earnings Call Transcript
Aug 05, 2021

$7.57 (+0.93%)

Earnings
Lumos Pharma Inc Clinical Updates Call Transcript
Jul 21, 2021
Lumos Pharma Inc Annual Shareholders Meeting Transcript
May 19, 2021
Q1 2021 Lumos Pharma Inc Earnings Call Transcript
May 05, 2021

$10.5 (-7.41%)

Earnings
Lumos Pharma Inc Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study-Corporate Call Transcript
Apr 27, 2021
Full Year 2020 Lumos Pharma Inc Earnings Call Transcript
Mar 09, 2021

$12.93 (-2.12%)

Earnings
Q3 2020 Lumos Pharma Inc Earnings Call Transcript
Nov 10, 2020

$14.56 (-1.50%)

Earnings
Q2 2020 Lumos Pharma Inc Earnings Call Transcript
Aug 13, 2020

$15.41 (+1.58%)

Earnings
Lumos Pharma Inc Annual Shareholders Meeting Transcript
Jul 28, 2020
Q1 2020 Lumos Pharma Inc Earnings Call Transcript
May 28, 2020

$14.5 (-2.03%)

Earnings
Q3 2019 NewLink Genetics Corp Earnings Call Transcript
Nov 06, 2019

$13.95 (-1.27%)

Earnings
NewLink Genetics Corp and Lumos Pharma Inc Enters Into A Definitive Merger Agreement - Conference Call Transcript
Oct 01, 2019
NewLink Genetics Corp at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019
Q1 2019 NewLink Genetics Corp Earnings Call Transcript
May 08, 2019

$15.03 (-6.18%)

Earnings
Q4 2018 NewLink Genetics Corp Earnings Call Transcript
Feb 27, 2019

$15.03 (+1.21%)

Earnings

Lumos Pharma Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 04:45PM GMT

Release Date Price: $3.73 (+2.75%)

Transcript

Unidentified Participant

Hello, everyone, welcome. Today we're conducting a fireside chat with Lumos Pharma. My name is [Mac Chandler]. I'm on the biotech equity research team here at Jefferies. And with me, I have John McKew, President and CSO; and Lori Lawley, the CFO of Lumos Pharma. So thank you for joining us today.

Questions & Answers

Unidentified Participant

Just to begin, can you give us an overview of idiopathic pediatric growth hormone deficiency and how that compares to organic and a little bit about how that delineation impacts the development program for LUM-201?

John McKew

Lumos Pharma, Inc. - President & Chief Scientific Officer

Sure, would be happy to, Mac. So growth hormone deficiency is a spectrum from very growth them inefficient all the way up to just below normal. And across this kind of spectrum of growth hormone deficiency, there is a group of patients who are quite growth hormone deficient and maybe they have a break in their ability to have hypothalamic regulation of the pituitary release of

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.